Table 2.

Correlates of antigen-specific T- and B-cell response following booster vaccination.

		Spike-specific T cells (ELISpot; N = 190)			RBD-specific B cells (n = 136)
Covariate	Level	N	Odds ratio (95% CI)	P value	N	Odds ratio (95% CI)	P value
Sex	Female	87	1.50 (0.80–2.81)	0.209	63	0.99 (0.48–2.03)	0.980
	Male	103	—	—	73	—	—
Race	Black	79	1.57 (0.81–3.03)	0.182	62	1.09 (0.52–2.31)	0.818
	Othera	105	—	—	67	—	—
Age ≤65	Yes	91	0.66 (0.35–1.25)	0.201	64	1.45 (0.70–2.99)	0.321
	No	99	—	—	72	—	—
Prior LOT (>2)	Yes	57	0.70 (0.34–1.43)	0.325	42	0.43 (0.19–0.96)	0.041
	No	124	—	—	89	—	—
Prior SARS-CoV-2 exposureb,c	Positive	47	2.18 (1.14–4.18)	0.019	31	5.39 (1.82–15.97)	0.002
	Negative	135	—	—	103	—	—
IgG ≤400	Yes	53	0.49 (0.25–0.96)	0.039	40	0.30 (0.13–0.70)	0.005
	No	137	—	—	96	—	—
Vaccine type	No booster	31	1.05 (0.47–2.34)	0.908	30	1.22 (0.48–3.13)	0.672
	Moderna	45	1.39 (0.63–3.08)	0.420	32	1.24 (0.49–3.15)	0.657
	Pfizer	88	—	—	59	—	—
Anti-CD38	Yes	56	0.70 (0.35–1.42)	0.323	40	0.75 (0.34–1.67)	0.477
	No	134	—	—	96	—	—
Lenalidomide maintenance	Yes	38	2.03 (0.94–4.37)	0.071	24	1.67 (0.68–4.07)	0.261
	No	152	—	—	112	—	—
Anti-BCMA	Yes	5	0.91 (0.52–1.62)	0.761	3	0.46 (0.32–0.66)	<0.001
	No	185	—	—	133	—	—
Dose type	Boost	60	1.59 (0.96–2.62)	0.069	36	1.30 (0.64–2.62)	0.465
	Dose 2	130	—	—	100	—	—

NOTE: Odds of ELISpot ≥ 33 and odds of RBD B cells ≥ 0.024 are reported. Sample size N reflects the number of observations, rather than the number of patients.

Abbreviations: LOT, lines of therapy; IgG, immunoglobulin G.

^aAmong the 105 Other race in ELISpot data, 103 were White, 1 Asian, and 1 Native American. Among the 67 Other race in B cell data, 65 were White, 1 Asian, and 1 Native American.

^b P < 0.05 on MVA for ELISpot.

^c P < 0.05 on MVA for RBD B cells.